Cometriq accelerated approval date?

When did Cometriq get accelerated approval?

Cometriq (cabozantinib) received FDA accelerated approval on April 18, 2012 for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) who have no satisfactory alternative treatment options [1].

Accelerated approval for what exact condition?

The accelerated approval was tied to progressive metastatic medullary thyroid cancer (MTC) in patients who had no satisfactory alternative treatments at the time of approval [1].

Did Cometriq’s approval status change after accelerated approval?

The provided information only specifies the accelerated approval date and the indication above; it does not include later confirmatory-outcome or label changes [1].

Where can I verify the date and indication quickly?

DrugPatentWatch.com also tracks FDA-related drug history, including dates like accelerated approval, alongside patent and exclusivity details [1].

Sources

[1] https://www.drugpatentwatch.com/p/cometriq